Endometrial Cancer Trial, Recruiting NCT06269809 Sponsor: Universitaire Ziekenhuizen KU Leuven Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT06269809
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given voluntary written consent to participate before any screening takes place (or whose legal representative has done so on their behalf)
  • People who are using a highly effective form of contraception, such as implants, injections, combined oral contraceptive pills, certain IUDs, complete abstinence from heterosexual intercourse during the trial period, or whose partner has had a vasectomy
  • People who are female
  • People aged between 18 and 50 years
  • People who have uterine fibroids (myomas) that are considered suitable for surgical removal (myomectomy), excluding certain fibroid types classified as FIGO type 7 or 8 (confirm with trial site)

Who may not be able to join:

  • People who have any medical condition that, in the opinion of the investigator, could put them at risk or affect their ability to follow the trial requirements
  • People who are receiving or have received other treatments that could affect their safety or interfere with the trial results
  • People who are currently participating in another clinical trial involving an investigational medicine or medical device
  • People who do not wish to participate in the trial
  • People who have a known or suspected cancer or malignancy
  • People who have any medical reason that would make laparoscopic or robotic surgery unsafe or unsuitable for them

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Wouter Froyman, MD, PhD, Universitaire Ziekenhuizen KU Leuven

Phone: +3216348826

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
4 May 2023
Est. completion
30 May 2025

Where this trial is recruiting

🇧🇪 Belgium 🇫🇷 France 🇳🇱 Netherlands

Primary endpoints

Peri-operative blood loss: Estimated blood loss; Peri-operative blood loss: Hemoglobin drop perioperatively >2g/dL; Peri-operative blood loss: Need for peri-operative blood transfusion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov